Dr. Verschraegen on Combining Immunotherapy Agents in Lung Cancer

Claire Verschraegen, MD
Published: Wednesday, Jun 21, 2017



Claire Verschraegen, MD, professor of medical oncology, University of Vermont Cancer Center, discussing combining avelumab (Bavencio) with other immunotherapy agents for patients with lung cancer.

Avelumab is different from pembrolizumab (Keytruda) or nivolumab (Opdivo) because it is a PD-L1 monoclonal antibody. Therefore, combining these agents can potentially create a higher benefit for patients.
 
SELECTED
LANGUAGE


Claire Verschraegen, MD, professor of medical oncology, University of Vermont Cancer Center, discussing combining avelumab (Bavencio) with other immunotherapy agents for patients with lung cancer.

Avelumab is different from pembrolizumab (Keytruda) or nivolumab (Opdivo) because it is a PD-L1 monoclonal antibody. Therefore, combining these agents can potentially create a higher benefit for patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x